JP2022521610A5 - - Google Patents
Info
- Publication number
- JP2022521610A5 JP2022521610A5 JP2021549746A JP2021549746A JP2022521610A5 JP 2022521610 A5 JP2022521610 A5 JP 2022521610A5 JP 2021549746 A JP2021549746 A JP 2021549746A JP 2021549746 A JP2021549746 A JP 2021549746A JP 2022521610 A5 JP2022521610 A5 JP 2022521610A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- cancer
- met
- seq
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024108371A JP2024153659A (ja) | 2019-02-26 | 2024-07-04 | 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化 |
| JP2025014414A JP2025084739A (ja) | 2019-02-26 | 2025-01-30 | 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962810716P | 2019-02-26 | 2019-02-26 | |
| US62/810,716 | 2019-02-26 | ||
| US201962930190P | 2019-11-04 | 2019-11-04 | |
| US62/930,190 | 2019-11-04 | ||
| PCT/IB2020/051559 WO2020174370A2 (en) | 2019-02-26 | 2020-02-24 | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024108371A Division JP2024153659A (ja) | 2019-02-26 | 2024-07-04 | 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化 |
| JP2025014414A Division JP2025084739A (ja) | 2019-02-26 | 2025-01-30 | 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022521610A JP2022521610A (ja) | 2022-04-11 |
| JP2022521610A5 true JP2022521610A5 (enExample) | 2023-07-24 |
| JP7703448B2 JP7703448B2 (ja) | 2025-07-07 |
Family
ID=72142314
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549746A Active JP7703448B2 (ja) | 2019-02-26 | 2020-02-24 | 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化 |
| JP2024108371A Pending JP2024153659A (ja) | 2019-02-26 | 2024-07-04 | 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化 |
| JP2025014414A Pending JP2025084739A (ja) | 2019-02-26 | 2025-01-30 | 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024108371A Pending JP2024153659A (ja) | 2019-02-26 | 2024-07-04 | 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化 |
| JP2025014414A Pending JP2025084739A (ja) | 2019-02-26 | 2025-01-30 | 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体による併用療法及び患者層別化 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11459391B2 (enExample) |
| EP (1) | EP3931224A4 (enExample) |
| JP (3) | JP7703448B2 (enExample) |
| KR (1) | KR20210132117A (enExample) |
| CN (1) | CN113840842A (enExample) |
| AU (1) | AU2020229467A1 (enExample) |
| BR (1) | BR112021016149A2 (enExample) |
| CA (1) | CA3131654A1 (enExample) |
| IL (1) | IL285718A (enExample) |
| JO (1) | JOP20210233A1 (enExample) |
| MA (1) | MA55089A (enExample) |
| MX (1) | MX2021010265A (enExample) |
| NZ (1) | NZ778579A (enExample) |
| PH (1) | PH12021552030A1 (enExample) |
| SG (1) | SG11202108311RA (enExample) |
| WO (1) | WO2020174370A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021016149A2 (pt) | 2019-02-26 | 2021-10-13 | Janssen Biotech, Inc. | Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met |
| EP3956035A4 (en) * | 2019-04-17 | 2023-01-25 | Board of Regents, The University of Texas System | ANTI-CANCER LINKS WITH TYROSINE KINASE RESISTANT EGFR MUTATIONS |
| MX2021013955A (es) * | 2019-05-14 | 2022-03-11 | Janssen Biotech Inc | Terapias de combinación con anticuerpos anti-egfr/c-met biespecíficos e inhibidores de tirosina quinasa de egfr de 3.a generación. |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| US11879013B2 (en) * | 2019-05-14 | 2024-01-23 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
| JP7783182B2 (ja) * | 2020-02-12 | 2025-12-09 | ヤンセン バイオテツク，インコーポレーテツド | ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療 |
| CN116194141A (zh) | 2020-08-25 | 2023-05-30 | 詹森生物科技公司 | 具有egfr突变的非小细胞肺癌的治疗 |
| BR112023018278A2 (pt) * | 2021-03-09 | 2023-10-31 | Janssen Biotech Inc | Tratamento de cânceres sem mutações de ativação de egfr |
| EP4372001A4 (en) * | 2021-07-14 | 2025-02-12 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | ANTIGEN-BINDING MOLECULE SPECIFICALLY BINDING TO HGFR AND EGFR, AND PHARMACEUTICAL USE THEREOF |
| CN118043075A (zh) * | 2021-07-29 | 2024-05-14 | 得克萨斯州大学系统董事会 | 用于治疗kras突变体癌症的方法和组合物 |
| KR102793991B1 (ko) | 2021-10-06 | 2025-04-09 | 주식회사 엘지에너지솔루션 | 태양광 시스템과 연계하는 에너지 저장 시스템 및 에너지 저장 시스템의 제어 방법 |
| US20230183360A1 (en) * | 2021-12-09 | 2023-06-15 | Janssen Biotech, Inc. | Use of Amivantamab to Treat Colorectal Cancer |
| WO2024189544A1 (en) * | 2023-03-13 | 2024-09-19 | Janssen Biotech, Inc. | Combination therapies with bi-specific anti-egfr/c-met antibodies and anti-pd-1 antibodies |
| KR20260005269A (ko) * | 2023-04-24 | 2026-01-09 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | c-Met를 표적으로 하는 다중 특이성 항체 |
| CN119700964A (zh) * | 2023-09-28 | 2025-03-28 | 上海翰森生物医药科技有限公司 | 一种双特异性抗体在制备治疗癌症的药物中的用途 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| FR2858235B1 (fr) | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| ES2425749T3 (es) | 2004-03-31 | 2013-10-17 | The General Hospital Corporation | Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico |
| EP3042964A1 (en) | 2004-06-04 | 2016-07-13 | Genentech, Inc. | Egfr mutations |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| CN102580084B (zh) | 2005-01-21 | 2016-11-23 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
| EP2505591A1 (en) | 2005-02-11 | 2012-10-03 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for detecting a drug resistant EGFR mutant |
| MX2007009963A (es) | 2005-02-24 | 2007-09-26 | Amgen Inc | Mutaciones del receptor del factor de crecimiento epidermico. |
| NZ561211A (en) | 2005-03-25 | 2011-03-31 | Genentech Inc | Methods and compositions for modulating hyperstabilized C-met |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| AU2008239594B2 (en) | 2007-04-13 | 2013-10-24 | Beth Israel Deaconess Medical Center | Methods for treating cancer resistant to ErbB therapeutics |
| KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| US7892770B2 (en) | 2007-08-24 | 2011-02-22 | Van Andel Research Institute | Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| CA2716670A1 (en) * | 2008-03-06 | 2009-09-11 | Genentech, Inc. | Combination therapy with c-met and her antagonists |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| US8962808B2 (en) | 2010-05-05 | 2015-02-24 | The Research Foundation For The State University Of New York | EGFR-related polypeptides and methods of use |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| ES2860748T3 (es) | 2011-01-24 | 2021-10-05 | Gilead Sciences Inc | Anticuerpos selectivos para células que presentan EGFR con alta densidad |
| BR112013023918A2 (pt) | 2011-03-25 | 2016-12-13 | Glenmark Pharmaceuticals Sa | imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural |
| KR20130036993A (ko) | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체 |
| RU2654567C2 (ru) | 2011-10-11 | 2018-05-21 | Дженентек, Инк. | Улучшенная сборка биспецифических антител |
| BR112014010580B1 (pt) | 2011-11-04 | 2021-01-12 | Zymeworks, Inc. | constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado |
| US20170275367A1 (en) * | 2012-11-21 | 2017-09-28 | Janssen Biotech, Inc. | Bispecific EGFR/C-Met Antibodies |
| MX361088B (es) * | 2012-11-21 | 2018-11-26 | Janssen Biotech Inc | Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos. |
| WO2015043614A1 (en) * | 2013-09-26 | 2015-04-02 | Biontech Ag | Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis |
| CN106456749B (zh) * | 2014-03-11 | 2021-03-30 | 小利兰·斯坦福大学托管委员会 | 抗SIRPα抗体和双特异性巨噬细胞增强型抗体 |
| WO2015188777A1 (en) | 2014-06-12 | 2015-12-17 | Shanghai Fochon Pharmaceutical Co Ltd | Certain protein kinase inhibitors |
| HUE054848T2 (hu) | 2014-10-13 | 2021-09-28 | Yuhan Corp | Vegyületek és készítmények EGFR mutáns kináz aktivitás módosítására |
| EP3221358B1 (en) | 2014-11-18 | 2021-07-21 | Janssen Pharmaceutica, N.V. | Cd47 antibodies, methods, and uses |
| WO2016090174A1 (en) * | 2014-12-03 | 2016-06-09 | Auckland Uniservices, Ltd. | Kinase inhibitor prodrug for the treatment of cancer |
| US12595297B2 (en) * | 2015-05-12 | 2026-04-07 | In3Bio Ltd. | Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors |
| SMT202100230T1 (it) | 2015-10-23 | 2021-07-12 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Molecole di legame che inibiscono la crescita tumorale |
| EP3383435A4 (en) | 2015-11-30 | 2019-07-10 | Medimmune, LLC | OPTIMIZED RATES OF AMINO ACIDS AND SUGARS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS HAVING HIGH CONCENTRATIONS IN PROTEIN-BASED THERAPEUTICS |
| US10813933B2 (en) | 2016-05-17 | 2020-10-27 | Japanese Foundation For Cancer Research | Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance |
| CN116333130A (zh) | 2016-05-24 | 2023-06-27 | 英斯梅德股份有限公司 | 抗体及其制备方法 |
| GB201611123D0 (en) | 2016-06-27 | 2016-08-10 | Euremab Srl | Anti met antibodiesand uses thereof |
| HUE054571T2 (hu) | 2016-09-14 | 2021-09-28 | Merck Patent Gmbh | Hatékony tumorgátlásra szolgáló C-MET elleni ellenanyagok és ellenanyag-drog konjugátumaik |
| KR102771603B1 (ko) | 2016-11-17 | 2025-02-24 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물 |
| CA3054381A1 (en) | 2017-02-22 | 2018-08-30 | University Of Saskatchewan | Egfr-binding agents and uses thereof |
| AR111469A1 (es) | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| WO2020055643A2 (en) | 2018-09-04 | 2020-03-19 | Rain Therapeutics Inc. | Compounds, compositions and methods for treating or preventing her-driven cancers |
| BR112021016149A2 (pt) | 2019-02-26 | 2021-10-13 | Janssen Biotech, Inc. | Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met |
| MX2021011948A (es) | 2019-03-29 | 2022-01-04 | Univ Texas | Compuestos con actividad antitumoral contra células cancerígenas que llevan inserciones de exon 20 effr o her2. |
| CA3132816A1 (en) | 2019-04-17 | 2020-10-22 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing tyrosine kinase inhibitor resistant egfr mutations |
| EP3956035A4 (en) | 2019-04-17 | 2023-01-25 | Board of Regents, The University of Texas System | ANTI-CANCER LINKS WITH TYROSINE KINASE RESISTANT EGFR MUTATIONS |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| US11879013B2 (en) | 2019-05-14 | 2024-01-23 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
| TW202309094A (zh) * | 2021-05-18 | 2023-03-01 | 美商健生生物科技公司 | 用於識別癌症患者以進行組合治療之方法 |
-
2020
- 2020-02-24 BR BR112021016149-0A patent/BR112021016149A2/pt unknown
- 2020-02-24 US US16/798,662 patent/US11459391B2/en active Active
- 2020-02-24 PH PH1/2021/552030A patent/PH12021552030A1/en unknown
- 2020-02-24 SG SG11202108311RA patent/SG11202108311RA/en unknown
- 2020-02-24 EP EP20763439.5A patent/EP3931224A4/en active Pending
- 2020-02-24 AU AU2020229467A patent/AU2020229467A1/en active Pending
- 2020-02-24 MA MA055089A patent/MA55089A/fr unknown
- 2020-02-24 CN CN202080017112.1A patent/CN113840842A/zh active Pending
- 2020-02-24 JP JP2021549746A patent/JP7703448B2/ja active Active
- 2020-02-24 CA CA3131654A patent/CA3131654A1/en active Pending
- 2020-02-24 KR KR1020217030301A patent/KR20210132117A/ko active Pending
- 2020-02-24 WO PCT/IB2020/051559 patent/WO2020174370A2/en not_active Ceased
- 2020-02-24 NZ NZ778579A patent/NZ778579A/en unknown
- 2020-02-24 MX MX2021010265A patent/MX2021010265A/es unknown
-
2021
- 2021-08-18 IL IL285718A patent/IL285718A/en unknown
- 2021-08-23 JO JOP/2021/0233A patent/JOP20210233A1/ar unknown
-
2022
- 2022-08-03 US US17/817,295 patent/US12215161B2/en active Active
-
2024
- 2024-07-04 JP JP2024108371A patent/JP2024153659A/ja active Pending
- 2024-12-20 US US18/990,769 patent/US20250236675A1/en active Pending
-
2025
- 2025-01-30 JP JP2025014414A patent/JP2025084739A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022521610A5 (enExample) | ||
| Herpers et al. | Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR× LGR5 bispecific antibody with efficacy in epithelial tumors | |
| JP2024153659A5 (enExample) | ||
| Benson et al. | Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology | |
| Drilon et al. | Response to ERBB3-directed targeted therapy in NRG1-rearranged cancers | |
| Kozakiewicz et al. | Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma | |
| Dienstmann et al. | Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer | |
| Iyer et al. | Fibroblast growth factor receptor-3 in urothelial tumorigenesis | |
| Banerjee et al. | New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential | |
| Dienstmann et al. | Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer | |
| De Cuyper et al. | HER2 as a predictive biomarker and treatment target in colorectal cancer | |
| Suwaidan et al. | HER2 targeted therapy in colorectal cancer: New horizons | |
| Nagaraja et al. | Genomics and targeted therapies in gastroesophageal adenocarcinoma | |
| KR20210102341A (ko) | 항체-약물 컨쥬게이트와 parp 저해제의 조합 | |
| Richards et al. | Results of docetaxel plus oxaliplatin (DOCOX)±cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study | |
| Martin-Broto et al. | REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial | |
| Pietanza et al. | Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non–small-cell lung cancer | |
| JP2023513297A5 (enExample) | ||
| Geyer et al. | A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas | |
| Lindberg et al. | Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer | |
| CN112912403A (zh) | 治疗肿瘤的方法 | |
| Bozec et al. | Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives | |
| Vera et al. | Current controversies in the management of metastatic colorectal cancer | |
| JP2023539589A5 (enExample) | ||
| Rathore et al. | Liver endothelium promotes HER3-mediated cell survival in colorectal cancer with wild-type and mutant KRAS |